MX349176B - Transdermal drug delivery using an osmolyte and vasoactive agent. - Google Patents
Transdermal drug delivery using an osmolyte and vasoactive agent.Info
- Publication number
- MX349176B MX349176B MX2010004169A MX2010004169A MX349176B MX 349176 B MX349176 B MX 349176B MX 2010004169 A MX2010004169 A MX 2010004169A MX 2010004169 A MX2010004169 A MX 2010004169A MX 349176 B MX349176 B MX 349176B
- Authority
- MX
- Mexico
- Prior art keywords
- osmolyte
- vasoactive agent
- drug delivery
- transdermal drug
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00902—Plasters containing means
- A61F2013/00906—Plasters containing means for transcutaneous or transdermal drugs application
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A formulation and method for delivery of bioactive substances when applied to, or within, the skin or other exterior region of a mammal, for example, a patient, includes a vasoactive agent; an osmolyte; and an active ingredient. The formulation is sufficiently hygroscopic so as to create a condition of hypertonicity when absorbed by the skin. When the formulation is applied to the skin, the vasoactive agent can be delivered to the dermis so as to contact the vasculature of a patient.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9912908P | 2008-09-22 | 2008-09-22 | |
PCT/US2009/057916 WO2010034019A1 (en) | 2008-09-22 | 2009-09-22 | Transdermal drug delivery using an osmolyte and vasoactive agent |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2010004169A MX2010004169A (en) | 2010-10-05 |
MX349176B true MX349176B (en) | 2017-07-14 |
Family
ID=41449932
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010004169A MX349176B (en) | 2008-09-22 | 2009-09-22 | Transdermal drug delivery using an osmolyte and vasoactive agent. |
Country Status (7)
Country | Link |
---|---|
US (3) | US9566256B2 (en) |
EP (1) | EP2207536A1 (en) |
BR (1) | BRPI0914192A2 (en) |
CA (1) | CA2702604C (en) |
CO (1) | CO6361907A2 (en) |
MX (1) | MX349176B (en) |
WO (1) | WO2010034019A1 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0914192A2 (en) | 2008-09-22 | 2015-11-03 | Biochemics Inc | transdermal drug delivery using an osmolyte and vasoactive agent |
WO2010065922A2 (en) * | 2008-12-04 | 2010-06-10 | Biochemics, Inc. | Methods and compositions for tattoo removal |
AU2011246881B2 (en) | 2010-04-28 | 2016-02-11 | Sorrento Therapeutics, Inc. | Composite microneedle array including nanostructures thereon |
CA2796965C (en) | 2010-04-28 | 2019-04-16 | Kimberly-Clark Worldwide, Inc. | Method for increasing permeability of an epithelial barrier |
CA2797204C (en) | 2010-04-28 | 2018-06-12 | Kimberly-Clark Worldwide, Inc. | Device for delivery of rheumatoid arthritis medication |
RU2585138C2 (en) | 2010-04-28 | 2016-05-27 | Кимберли-Кларк Ворлдвайд, Инк. | Medical devices for delivery of sirna |
US8512770B2 (en) | 2010-08-04 | 2013-08-20 | Dominion Resources Unlimited, Llc | Skin penetration composition |
US20170246439A9 (en) | 2011-10-27 | 2017-08-31 | Kimberly-Clark Worldwide, Inc. | Increased Bioavailability of Transdermally Delivered Agents |
US11110066B2 (en) | 2011-10-27 | 2021-09-07 | Sorrento Therapeutics, Inc. | Implantable devices for delivery of bioactive agents |
CN104039382B (en) | 2011-10-27 | 2018-01-12 | 金伯利-克拉克环球有限公司 | The dermal delivery of high viscosity bioactivator |
AU2012348700B2 (en) | 2011-12-06 | 2015-08-27 | Unilever Plc | Skin anti-ageing composition |
US9587169B2 (en) * | 2012-01-12 | 2017-03-07 | Courtney Gene Rogers | Low-toxicity, low-flammability, environmentally-safe, friction reducer fluid for hydraulic fracturing |
US20160058725A1 (en) * | 2013-03-15 | 2016-03-03 | Biochemics, Inc. | Topical Formulations and Methods for Drug Delivery |
WO2015066699A1 (en) * | 2013-11-04 | 2015-05-07 | ROGERS, Courtney, Gene | Low-toxicity, low-flammability, environmentally-safe, friction reducer fluid for hydraulic fracturing |
WO2018213071A1 (en) | 2017-05-15 | 2018-11-22 | Biochemics, Inc. | Transdermally-delivered combination drug therapy for pain |
US11103465B2 (en) | 2017-11-22 | 2021-08-31 | Ted's Brain Science, Inc. | Trans-resveratrol topical medication for the treatment of pain and method of manufacture thereof |
IT201800003902A1 (en) * | 2018-03-23 | 2019-09-23 | Sebastiano Turrini | OIL BASED ON TRANSEDERMIC RACEMIC IBUPROPHEN |
CA3112808A1 (en) * | 2018-09-27 | 2020-04-02 | BioPhysics Pharma, Inc. | Transdermal drug delivery system |
CA3168441A1 (en) * | 2020-02-20 | 2021-08-26 | North Atlantic Holdings LLC | Transmucosal drug delivery system |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4440777A (en) * | 1981-07-07 | 1984-04-03 | Merck & Co., Inc. | Use of eucalyptol for enhancing skin permeation of bio-affecting agents |
US4933184A (en) * | 1983-12-22 | 1990-06-12 | American Home Products Corp. (Del) | Menthol enhancement of transdermal drug delivery |
US4758599A (en) * | 1986-06-04 | 1988-07-19 | American Cyanamid Company | Clear, hydroalcoholic aftershave lotion which moisturizes, conditions, and prevents irritation |
US4830856A (en) * | 1987-01-27 | 1989-05-16 | Peppers James M | Chelation product |
US4859704A (en) | 1987-10-15 | 1989-08-22 | Oratech Pharmaceutical Development Corporation | Water soluble ibuprofen compositions and methods of making them |
GB8905815D0 (en) | 1989-03-14 | 1989-04-26 | Beecham Group Plc | Medicament |
AU6974191A (en) | 1989-12-20 | 1991-07-18 | Schering Corporation | Stable cream and lotion bases for lipophilic drug compositions |
US5093133A (en) | 1990-01-24 | 1992-03-03 | Mcneil-Ppc, Inc. | Method for percutaneous delivery of ibuprofen using hydroalcoholic gel |
US5210099A (en) | 1991-02-11 | 1993-05-11 | American Home Products Corporation | Analgesic compositions |
HU219242B (en) | 1991-05-13 | 2001-03-28 | Boots Co Plc | S(+)-ibuprofen sodium salt dihydrate, pharmaceutical composition comprising this compound and process for production of them |
US5229130A (en) * | 1991-12-20 | 1993-07-20 | Cygnus Therapeutics Systems | Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems |
US5451704A (en) | 1992-12-23 | 1995-09-19 | Mobil Oil Corporation | Alpha-olefin oligomerization using supported metal halide catalysts |
US5451407A (en) * | 1993-06-21 | 1995-09-19 | Alza Corporation | Reduction or prevention of skin irritation or sensitization during transdermal administration of a irritating or sensitizing drug |
US5460821A (en) * | 1993-06-23 | 1995-10-24 | Masiz; John J. | Molecular transdermal transport system |
US5645854A (en) * | 1993-06-23 | 1997-07-08 | Masiz; John J. | Molecular transdermal transport system |
US5853751A (en) * | 1993-06-23 | 1998-12-29 | Masiz; John J. | Molecular transdermal transport system |
IT1265001B1 (en) | 1993-12-16 | 1996-10-17 | Zambon Spa | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE CONTAINING (S) -2- (4- ISOBUTYLPHENYL) PROPIONIC ACID |
DE19509807A1 (en) | 1995-03-21 | 1996-09-26 | Basf Ag | Process for the preparation of active substance preparations in the form of a solid solution of the active substance in a polymer matrix, and active substance preparations produced using this method |
US5527530A (en) * | 1994-07-08 | 1996-06-18 | The Procter & Gamble Company | Alcoholic moisturizing after shave lotion |
US5496827A (en) * | 1994-07-15 | 1996-03-05 | Patrick; Jay | Compositions for the transdermal delivery of nutrients |
US6228873B1 (en) * | 1994-12-09 | 2001-05-08 | The Regents Of The University Of California | Method for enhancing outflow of aqueous humor in treatment of glaucoma |
US5654337A (en) | 1995-03-24 | 1997-08-05 | II William Scott Snyder | Topical formulation for local delivery of a pharmaceutically active agent |
FR2732221B1 (en) * | 1995-03-28 | 1997-04-25 | Oreal | USE OF A CGRP ANTAGONIST TO TREAT CUTANEOUS REDNESS OF NEUROGENIC ORIGIN AND COMPOSITION OBTAINED |
FR2741262B1 (en) * | 1995-11-20 | 1999-03-05 | Oreal | USE OF A TNF-ALPHA ANTAGONIST FOR THE TREATMENT OF CUTANEOUS REDNESS OF NEUROGENIC ORIGIN |
AU703540B2 (en) * | 1996-03-26 | 1999-03-25 | Meddiss, Incorporated | Methods for inducing analgesia or anesthesia and treating or preventing ischemic injury of tissues in general |
US6527716B1 (en) * | 1997-12-30 | 2003-03-04 | Altea Technologies, Inc. | Microporation of tissue for delivery of bioactive agents |
EP0973384A4 (en) * | 1997-02-13 | 2004-10-13 | Sky High Llc | Organ preservation solution |
US5980882A (en) * | 1997-04-16 | 1999-11-09 | Medeva Pharmaceuticals Manufacturing | Drug-resin complexes stabilized by chelating agents |
US6248763B1 (en) * | 1998-05-19 | 2001-06-19 | Scivoletto Rosemarie | Composition for treating skin conditions |
US5976566A (en) | 1997-08-29 | 1999-11-02 | Macrochem Corporation | Non-steroidal antiinflammtory drug formulations for topical application to the skin |
US6207713B1 (en) * | 1997-09-17 | 2001-03-27 | Eric T. Fossel | Topical and oral delivery of arginine to cause beneficial effects |
US5922332A (en) * | 1997-09-17 | 1999-07-13 | Fossel; Eric T. | Topical delivery of arginine to overcome pain |
US5895658A (en) * | 1997-09-17 | 1999-04-20 | Fossel; Eric T. | Topical delivery of L-arginine to cause tissue warming |
US6486206B1 (en) * | 1997-09-29 | 2002-11-26 | Cprx Inc. | Mechanical and pharmacologic therapies to treat cardiac arrest |
WO1999051157A1 (en) * | 1998-04-07 | 1999-10-14 | The General Hospital Corporation | Apparatus and methods for removing blood vessels |
US6477410B1 (en) * | 2000-05-31 | 2002-11-05 | Biophoretic Therapeutic Systems, Llc | Electrokinetic delivery of medicaments |
CA2374003C (en) * | 1999-05-17 | 2008-02-12 | Aesgen, Inc. | Improved cellular uptake of bioactive agents |
US6368618B1 (en) | 1999-07-01 | 2002-04-09 | The University Of Georgia Research Foundation, Inc. | Composition and method for enhanced transdermal absorption of nonsteroidal anti-inflammatory drugs |
ITMI991894A1 (en) | 1999-09-09 | 2001-03-09 | Carlo Ghisalberti | CONJUGATED LINOLEIC ACID AND TRIGLYCERIDE NEW METHODS OF SYNTHESIS AND USE |
US7105172B1 (en) * | 1999-11-18 | 2006-09-12 | Bolla John D | Treatment of rosacea |
FR2808191B1 (en) * | 2000-04-28 | 2004-03-05 | Oreal | PLANT EXTRACT OF THE SPECIES OLEA EUROPAEA AS NO-SYNTHASE INHIBITOR AND USES |
AU2001290552A1 (en) * | 2000-09-15 | 2002-03-26 | Medical Merchandising, Inc. | Pain reliever and method of use |
US6635274B1 (en) * | 2000-10-27 | 2003-10-21 | Biochemics, Inc. | Solution-based transdermal drug delivery system |
US7041657B2 (en) * | 2001-02-12 | 2006-05-09 | Marine Polymer Technologies Inc. | Compositions and methods for modulation of vascular structure and/or function |
US6936589B2 (en) * | 2001-09-28 | 2005-08-30 | Albert T. Naito | Parenteral delivery systems |
US20030091659A1 (en) * | 2001-11-09 | 2003-05-15 | Avon Products, Inc. | Topical composition having undifferentiated plant seed cells and method for using same |
US20030104043A1 (en) * | 2001-12-03 | 2003-06-05 | Brown Beverly Ann | Topical cream for alleviating spider veins |
US7041677B2 (en) * | 2002-03-01 | 2006-05-09 | R.T. Alamo Ventures I, Llc | Use of monochloroflosequinan in the treatment of sexual dysfunction |
EP1483368A2 (en) * | 2002-03-08 | 2004-12-08 | McGill University | In vitro maturation of immature human oocytes |
US20030206946A1 (en) * | 2002-04-26 | 2003-11-06 | Yih-Lin Chung | Methods for therapy of connective tissue disease |
CN1655762B (en) | 2002-06-17 | 2010-05-26 | 塔罗制药美国公司 | Ibuprofen suspension |
US20050271596A1 (en) * | 2002-10-25 | 2005-12-08 | Foamix Ltd. | Vasoactive kit and composition and uses thereof |
US20070292461A1 (en) | 2003-08-04 | 2007-12-20 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
EP1603476A4 (en) * | 2003-03-13 | 2010-01-13 | 3M Innovative Properties Co | Method of tattoo removal |
US6927206B2 (en) * | 2003-06-06 | 2005-08-09 | Procyte Corporation | Compositions and methods for treatment of rosacea |
US20080112909A1 (en) * | 2003-06-24 | 2008-05-15 | Ppg Industries Ohio, Inc. | Compositions for providing color to animate objects and related methods |
US7375139B2 (en) * | 2003-08-18 | 2008-05-20 | Aldred Katherine M | Transdermal method and apparatus |
AU2004277977B2 (en) * | 2003-09-30 | 2010-10-28 | Biomechanisms Inc. | Compositions and methods for treating burns |
ITMI20032322A1 (en) * | 2003-11-27 | 2005-05-28 | Carlo Ghisalberti | NON-TOXIC DEVICE TO FACILITATE VENIPUNTURA. |
CA2558439A1 (en) | 2004-03-11 | 2005-10-06 | Kythera Biopharmaceuticals, Inc. | Compositions and methods for preventing and treating skin and hair conditions |
EP1588697A1 (en) | 2004-04-16 | 2005-10-26 | Kurt H. Prof. Dr. Bauer | Emulsion gel for topical application of pharmaceuticals |
AU2005235309B2 (en) * | 2004-04-19 | 2012-07-26 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
US20050256204A1 (en) * | 2004-05-11 | 2005-11-17 | Bitter Patrick H Sr | Topical phenyl-epinephrine Rosacea treatment |
GB0413635D0 (en) | 2004-06-18 | 2004-07-21 | Smith & Nephew | Ultrasonic treatment |
US20060013769A1 (en) * | 2004-07-16 | 2006-01-19 | Stephen Carter | Transdermal drug delivery formulations and method of determining optimal amounts of vasodilators therein |
US20060013866A1 (en) * | 2004-07-16 | 2006-01-19 | Carter Stephen G | Transdermal drug delivery formulations with optimal amounts of vasodilators therein |
US7288263B2 (en) * | 2004-09-13 | 2007-10-30 | Evera Laboratories, Llc | Compositions and methods for treatment of skin discoloration |
US20060062836A1 (en) * | 2004-09-21 | 2006-03-23 | Carter Stephen G | Methods of device-assisted drug delivery |
US20060217690A1 (en) * | 2005-03-22 | 2006-09-28 | Bastin Norman J | Method for treating various dermatological and muscular conditions using electromagnetic radiation |
WO2006104660A1 (en) | 2005-03-24 | 2006-10-05 | Avery Dennison Corporation | Occlusive wound dressing useful in tattoo removal |
DE102005055275A1 (en) * | 2005-11-17 | 2007-05-24 | Ursapharm Arzneimittel Gmbh & Co. Kg | Phosphate-free pharmaceutical composition and its use |
US20070166252A1 (en) * | 2005-12-30 | 2007-07-19 | Judy Hattendorf | Method of treating skin requiring tattoo removal |
WO2007086395A1 (en) | 2006-01-24 | 2007-08-02 | Hamamatsu Foundation For Science And Technology Promotion | Photodynamic therapy kit |
US20070178121A1 (en) * | 2006-01-27 | 2007-08-02 | Allergan, Inc. | Methods for enhancing skin treatments |
CA2645073A1 (en) | 2006-03-08 | 2007-09-13 | Nuviance, Inc. | Transdermal drug delivery compositions and topical compositions for application on the skin |
WO2007143002A2 (en) * | 2006-05-31 | 2007-12-13 | Interhealth Nutraceuticals, Inc. | Nutraceutical treatments for diabetic and non-diabetic wound healing |
WO2008047680A1 (en) | 2006-10-12 | 2008-04-24 | Rohto Pharmaceutical Co., Ltd. | External preparation for skin |
KR101069502B1 (en) | 2006-10-31 | 2011-09-30 | (주)아모레퍼시픽 | Oral compositions for the improvement of obesity and diabetes |
WO2008109124A1 (en) | 2007-03-06 | 2008-09-12 | Novalar Pharmaceuticals, Inc. | Use of nitroglycerin to reverse local anesthesia |
AU2008229385A1 (en) * | 2007-03-19 | 2008-09-25 | Sirtris Pharmaceuticals, Inc. | Biomarkers of sirtuin activity and methods of use thereof |
US8354116B2 (en) * | 2007-06-18 | 2013-01-15 | Biochemics, Inc. | Bifunctional synthetic molecules |
US20090123570A1 (en) * | 2007-11-09 | 2009-05-14 | Warner W Randolph | Composition and method for treating sore throat |
US8343486B2 (en) * | 2008-01-22 | 2013-01-01 | Biochemics, Inc. | Methods and compositions for topical treatment of medical conditions including wounds and inflammation |
US20090227936A1 (en) | 2008-03-07 | 2009-09-10 | Frank Pellegrini | Ultra bright LED induced tattoo removal |
EP2307001A1 (en) * | 2008-06-11 | 2011-04-13 | BioChemics, Inc. | Control of blood vessel physiology to treat skin disorders |
CA2726726A1 (en) | 2008-09-10 | 2010-03-18 | Thrubit B.V. | Ibuprofen for topical administration |
BRPI0914192A2 (en) * | 2008-09-22 | 2015-11-03 | Biochemics Inc | transdermal drug delivery using an osmolyte and vasoactive agent |
WO2010065922A2 (en) * | 2008-12-04 | 2010-06-10 | Biochemics, Inc. | Methods and compositions for tattoo removal |
-
2009
- 2009-09-22 BR BRPI0914192A patent/BRPI0914192A2/en not_active IP Right Cessation
- 2009-09-22 WO PCT/US2009/057916 patent/WO2010034019A1/en active Application Filing
- 2009-09-22 EP EP09740777A patent/EP2207536A1/en not_active Withdrawn
- 2009-09-22 US US12/564,841 patent/US9566256B2/en active Active
- 2009-09-22 MX MX2010004169A patent/MX349176B/en active IP Right Grant
- 2009-09-22 CA CA2702604A patent/CA2702604C/en not_active Expired - Fee Related
-
2011
- 2011-04-12 CO CO11045145A patent/CO6361907A2/en not_active Application Discontinuation
-
2015
- 2015-12-28 US US14/980,348 patent/US10537536B2/en not_active Expired - Fee Related
-
2016
- 2016-01-15 US US14/996,968 patent/US10751309B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2010034019A1 (en) | 2010-03-25 |
US20160129116A1 (en) | 2016-05-12 |
CA2702604A1 (en) | 2010-03-25 |
EP2207536A1 (en) | 2010-07-21 |
CA2702604C (en) | 2013-12-03 |
US20160128957A1 (en) | 2016-05-12 |
US9566256B2 (en) | 2017-02-14 |
US10751309B2 (en) | 2020-08-25 |
US10537536B2 (en) | 2020-01-21 |
MX2010004169A (en) | 2010-10-05 |
WO2010034019A4 (en) | 2010-05-20 |
US20100076035A1 (en) | 2010-03-25 |
BRPI0914192A2 (en) | 2015-11-03 |
CO6361907A2 (en) | 2012-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2010004169A (en) | Transdermal drug delivery using an osmolyte and vasoactive agent. | |
AR077484A1 (en) | FORMULATION OF GLATIRAMER ACETATE OF REDUCED VOLUME AND METHODS FOR ADMINISTRATION | |
WO2010068281A3 (en) | Contact lens drug delivery device | |
EA200901112A1 (en) | LIQUID COMPOSITIONS FORMING DERMAL FILMS FOR INTRODUCTION OF MEDICINAL PREPARATIONS IN THE SKIN | |
NZ701915A (en) | High-concentration monoclonal antibody formulations | |
WO2010056922A3 (en) | Systems and methods for delivery of biologically active agents | |
WO2011053792A3 (en) | Methods and compositions for sustained delivery of drugs | |
WO2011107755A3 (en) | Immediate/delayed drug delivery | |
JP2017500374A5 (en) | ||
WO2009029958A3 (en) | Implantable delivery device | |
JP2016539921A5 (en) | ||
NZ599265A (en) | A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof | |
IN2014DN09817A (en) | ||
MX2012000275A (en) | Acid pump antagonist for treatment of diseases associated with abnormal gastrointestinal movement. | |
NZ611920A (en) | Percutaneous absorption preparation containing rivastigmine | |
MX2009011900A (en) | Diabetic wound healing. | |
MX2011011058A (en) | Selective ep4 receptor agonistic substance for treatment of cancer. | |
IL273329A (en) | Modulation of heparin-binding epidermal growth factor activity for tympanic membrane healing | |
WO2008051527A3 (en) | Sustained release of agents for localized pain management | |
WO2008114376A1 (en) | Melanogenesis inhibitory composition | |
WO2012106058A3 (en) | Animal treatments | |
MX341660B (en) | Ghrelin receptor agonist for treatment of dyscrasia. | |
WO2012145554A3 (en) | Method of producing substances with supersaturated gas,transdermal delivery device thereof, and uses thereof | |
WO2015100348A8 (en) | Keloid reduction using topical allantoin | |
WO2006091763A3 (en) | Ultrasonically assisted dermal or transdermal delivery substance preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |